Why DEFLUX

The next Febrile UTI could scar a child for life1
Stop Febrile UTI in their tracks

  • A minimally invasive endoscopic injection4,5
  • Reduces febrile UTIs nearly 4x better than antibiotic prophylaxis and comparable to surgery7
  • Durable protection against febrile UTI with an excellent safety profile5,6
  • 5 to 15 minute procedure4
  • 10 years on the market6
  • More than 50,000 children treated6


1. American Academy of Pediatrics. Committee on Quality Improvement, Subcommittee on Urinary Tract Infection. Practice parameter. The diagnosis, treatment, and evaluation of the initial urinary tract infection in febrile infants and young children. Pediatrics. 1999;103(4):843-852.

4. Cerwinka WH, Scherz HC, Kirsch AJ. Endoscopic treatment of vesicoureteral reflux with dextranomer/hyaluronic acid in children. Adv Urol. Published Online: May 14, 2008 (doi:10.1155/2008/513854).

5. Deflux [package insert]. Raleigh, NC: Salix Pharmaceuticals, Inc.; 2009

6. Data on file. Salix Pharmaceuticals, Inc.

7. Elder JS, Shah MB, Batiste LR, Eaddy M. Part 3: endoscopic injection versus antibiotic prophylaxis in the reduction of urinary tract infections in patients with vesicoureteral reflux. In: Hensle TW. Challenges surrounding vesicoureteral reflux: fuel for a paradigm shift in treatment. Curr Med Res Opin. 2007;23(suppl 4):S15-S20.